This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Renovo Limited. Active years: 2011.
Company Filing History:
Years Active: 2011
Title: Emma Atkinson: Innovator in TGF-β3 Research
Introduction
Emma Atkinson is a prominent inventor based in Manchester, GB. She has made significant contributions to the field of biotechnology, particularly in the development of TGF-β3 mutants and their applications in medicine. With a total of 2 patents, her work is paving the way for advancements in wound treatment and fibrotic disorder management.
Latest Patents
Atkinson's latest patents focus on TGF-β3 mutants, which provide innovative solutions for medical treatments. One of her inventions details TGF-β3s, or fragments and derivatives thereof, that include alpha-helix-stabilizing substitutions in the domain between amino acid residues (58) and (67). Additionally, her work involves replacing the Glycine residue at position (63) with Proline and making substitutions at other critical positions. These inventions also encompass medicaments and methods of treatment utilizing such TGF-β3s. Another patent highlights the use of monomeric TGF-βs as medicaments, which can accelerate wound healing, inhibit scarring, promote epithelial regeneration, and prevent or treat fibrotic disorders.
Career Highlights
Emma Atkinson is currently associated with Renovo Limited, where she continues to innovate in her field. Her research has garnered attention for its potential impact on medical treatments and patient care.
Collaborations
Atkinson collaborates with notable colleagues, including Mark William James Ferguson and Nick Occleston, who contribute to her research endeavors and help advance her innovative projects.
Conclusion
Emma Atkinson's work in TGF-β3 research exemplifies the importance of innovation in biotechnology. Her patents and ongoing research are set to make a significant impact on the treatment of wounds and fibrotic disorders.